31 results about "Myc proteins" patented technology

The present invention provides methods for stabilizing pluripotent cells through the transcriptional activation of c-myc. Alternatively, the cells are stabilized through the transcriptional activation of c-myc, and the stabilization of c-myc protein levels. c-myc protein can be stabilized through the inhibition of GSK3β or through other components of the cellular machinery that impact on c-myc stability. The invention contemplates the stabilized pluripotent cells produced using the methods described herein. Methods for the identification of compounds that modulate the stabilization of pluripotent cells through modulating transcriptional activation of c-myc, stabilization of c-myc protein levels, and/or inhibition of GSK3β activity are also contemplated.

This invention provides small molecule Myc-inhibitors. Also provided in the invention are therapeutic applications of these compounds for treating Myc-driven cancer and other related methods.

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.

This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.

The invention aims at providing a reagent for detecting the interest protein expression condition in paraffin-embedded tissue. According to the technical scheme, a detection kit for evaluating prognosis information of an esophageal squamous carcinoma patient is provided. The kit comprises antibody primary antibody CD105 protein, esVEGFR2 protein and MYC protein antibodies for resisting three kinds of interest protein, and further comprises goat serum, 0.01M citrate restoration liquid, 3% H2O2, a Polymer enhancer, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating prognosis of the esophageal squamous carcinoma patient, and is simpler than international TNM staging and easy to carry out, the sensibility and specificity of the kit are both higher than those of TNM staging, and the kit is more suitable for esophageal squamous carcinoma prognosis evaluation of Chinese.

The invention discloses application of ELL as an E3 ubiquitin ligase. The application of ELL protein or truncated protein of the ELL protein to at least one of 1-6: 1, a protein product for degrading c-Myc is prepared; 2, the ELL protein or the truncated protein of the ELL protein is used as the E3 ubiquitin ligase; 3, a product for inhibiting tumor cell proliferation is prepared; 4, a product for inhibiting tumorigenesis is prepared; 5, a product for identifying or assisting in identifying whether tissue to be detected is tumor tissue or not is prepared; 6, a product for identifying or assisting in identifying whether a patient to be detected is a tumor patient or not is prepared. The experiment proves that ELL is combined with c-Myc and induces c-Myc to be degraded through proteasome, in-vivo and in-vitro studies both indicate that the ELL has the characteristic of the E3 ubiquitin ligase, can inhibit tumor cell proliferation and tumorigenesis, can be used as a molecular marker for tumor clinical diagnosis, and can be used for preparing the medicine or a kit for inhibiting tumors and a kit for diagnosing the tumors as the novel E3 ubiquitin ligase of c-Myc.

The invention relates to the production of hepatocyte cell lines useful in toxicology screens or therapy. A mammalian hepatocyte comprises, as a single polypeptide, a fusion protein comprising a c-myc protein and an oestrogen receptor, or functional fragments thereof.

The invention discloses a fluorescence spectrometry method for an oncogene C-myc protein. In the method, the determination basis is that the C-myc protein has fluorescence and has a fluorescence quenching phenomenon after combining with gold nano-sol; and the fluorescence quenching intensity (delta F) and the concentration change of the C-myc protein are in a linear corresponding relationship so as to fulfill the aim of determining the C-myc content. A C-myc protein sample is determined accurately by the method, the recovery rate of the C-myc is between 94.29 and 107.14 percent; the detectable C-myc protein concentration range is between 0 and 1,000 pmol/L; the linear range is between 87.5 and 875 pmol/L and between 0.175 and 17.5 pmol/L; and the detection limit is between 0.01 and 0.08 pmol/L. The determination method of the invention has the advantages of simple and convenient operation, wide linear range, high sensitivity, low detection limit, high stability and reproducibility and the like.

The invention relates to a c-Myc protein combinable DNA (Deoxyribonucleic Acid) segment. The c-Myc protein combinable DNA segment comprises one or more c-Myc protein combining frames, wherein the sequence of each c-Myc protein combining frame is 5'-SCACGTGS-3' and S represents C or G; the invention further relates application of the DNA segment; the invention further relates to a method for detecting transcriptional regulation activity of c-Myc protein in cells. By utilizing the DNA segment and the method, provided by the invention, the transcriptional regulation activity of the c-Myc protein in the cells can be directly and specifically detected and the content of transcripts or the protein is also detected, so that the effect of the c-Myc protein, which is used as a transcription factor, in development of certain diseases can be more accurately analyzed.

The invention relates to the field of medicines, and in particular relates to polypeptide which can inhibit MYC carcinogenic protein and treat tumor. The sequence of the polypeptide is as shown in SEQ ID NO.1. The polypeptide has the application of tumor treatment. The application includes tumor treatment in multiple administration modes, including subcutaneous or intramuscular injection, intravenous injection or intravenous drip, and the like. The polypeptide has the beneficial effects that in-vitro proliferation activity of multiple tumor cells can be inhibited, MYC protein expression in tumor cells can be promoted, telomerase activity of a tumor cell can be inhibited, growth of tumor inside tumor model naked mice can be inhibited, and the survival rate of tumor-bearing mice can be increased. An effect of treating tumor can be achieved.

The invention relates to a c-Myc protein inhibitor as well as a preparation method and application thereof, the c-Myc protein inhibitor can selectively inhibit c-Myc protein, so that the c-Myc protein inhibitor can be used for preventing and treating c-Myc protein disorder related diseases, such as cancer, cardiovascular and cerebrovascular diseases, virus infection related diseases and the like.

The present invention provides antisense oligoribonucleotides with sequences that recognize and bind to the c-myc gene or c-myc mRNA, where one or more sugar residues of the oligoribonucleotides are modified by the substitution of DNP at the 2′-O position. The antisense oligoribonucleotides can be used for inhibiting the growth of cells in which the c-myc gene is overexpressed by down-regulation of transcription of c-myc RNA or translation of the c-myc protein. The antisense oligoribonucleotides can also be used for diagnostic purposes to identify the overexpression of the c-myc gene. The nucleotide sequence of the DNP-oligoribonucleotides is complementary to the sequence 578 to 598 in c-myc mRNA and does not contain a G-quartet motif. This DNP-RNA can silence c-myc gene expression both in vitro and in vivo with high efficacy and sequence specificity.

The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

The invention discloses a marker for evaluating the risk of familial breast cancer, which is MYC gene or MYC protein, and further confirms that the expression of MYC is up-regulated in a breast cancersample. The molecular marker can be used to prepare early diagnosis reagent or kit for familial breast cancer, which can detect the occurrence and development trend of breast cancer in the high-riskpopulation of breast cancer earlier and more conveniently. At the same time, the molecular marker can be used to detect breast cancer and provide therapeutic targets and important basis for gene therapy, drug therapy and other clinical applications.

The invention discloses a polypeptide or derivatives thereof for promoting C-Myc protein degradation in a targeted way and application of the polypeptide or derivatives thereof in preparation of medicines for preventing and treating tumors. The polypeptide has an amino acid sequence as shown by substituting two or more amino acids in an amino acid sequence as shown in SEQ ID No.1 in a sequence table with unnatural amino acids with connectable side chains; the derivatives include chimeric peptides formed by linking the polypeptide and cell penetrating peptides, fusion peptides formed by the polypeptide and virus, the methylated polypeptide, the glycosylated polypeptide and the PEGylated polypeptide. The polypeptide or derivatives thereof can specifically bond with TRB3 to block interactionof TRB3 and C-Myc protein and promote degradation of the C-Myc protein, so that the polypeptide or derivatives thereof can be applied to preparation of medicines for preventing and treating tumors. The medicines prepared from the polypeptide or derivatives thereof have the advantages of remarkable curative effect, small toxic and side effect and safe use in tumor disease treatment.

Vectors and methods are disclosed for immortalizing mammalian cells by co-expression of v-raf and v-myc proteins. A replication-defective viral vector is used for improved safety. The vector comprises an optional marker gene, and is especially useful for producing an immortalized macrophage by a method that involves contacting the vector with a monocyte, proliferatively growing the monocyte, growing the monocytic cell on a solid surface, and then growing the monocytic cell on a porous surface. An immortalized macrophage is also disclosed.